I need to research the current situation with Eli Lilly, the Foundayo launch, and recent market dynamics.

Eli Lilly's Weight-Loss Pill Stumbled Out of the Gate — Can a $5 Billion Rebound Hold Without Stronger Prescriptions?

Shares shifted as Eli Lilly climbed +3.0% to $996.28 on May 12, defying a weak broader market (S&P 500 down 0.65%, Nasdaq down 1.54%) and extending a recovery that has added roughly $40 billion in market cap since Friday's low of $948.45. The catalyst: fading anxiety over a slower-than-hoped launch of Foundayo, the company's new once-daily weight-loss pill, which had rattled investors since early prescription data landed below the pace set by Novo Nordisk's rival pill.

• The Prescription Gap That Spooked Wall Street

In its second full week, Foundayo logged just 3,707 prescriptions — far short of the 18,410 Novo Nordisk's oral Wegovy posted in its comparable week.

That gap forced analysts to slash 2026 Foundayo revenue estimates from roughly $4–5 billion down to $1.3–1.6 billion. For shareholders, this isn't about one drug — it's about whether Lilly can defend its lead in the obesity market now worth hundreds of billions over the next decade.

• Most New Users Have Never Tried These Drugs Before

More than 80% of the 20,000-plus patients taking Foundayo are new to GLP-1 drugs. That is the single most important data point for bulls: Foundayo is not cannibalizing sales of Lilly's industry-leading injectables, Zepbound and Mounjaro. It's growing the pie, not slicing it differently.

• Lilly's Earnings Machine Keeps Covering the Gap

Q1 revenue soared 56% to $19.8 billion, net income more than doubled to $7.4 billion, and non-GAAP EPS of $8.55 crushed the $6.77 consensus.

Management raised full-year guidance to $82–$85 billion in revenue. Even if Foundayo underperforms near-term, Mounjaro and Zepbound sales surged 125% and 80% to $8.7 billion and $4.2 billion, respectively — enough firepower to absorb a slow pill ramp.

• The Real Marketing Push Hasn't Started

Lilly activated its in-person sales force only on April 17 and plans a broader promotional blitz in Q3, with coverage at two of three major pharmacy benefit managers confirmed and Medicare access beginning July 1.

Analysts maintain an average price target of roughly $1,200, implying over 20% upside. But realized prices fell 13% overall and 25% internationally — a pricing headwind that volume must keep outrunning. The rebound looks justified by fundamentals; sustaining it will require Foundayo prescriptions to accelerate before summer ends.